The Technical Analyst
Pacira Biosciences Inc [PCRX]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Pacira Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.57% $26.25
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 220.65 mill |
| EPS: | 0.890 |
| P/E: | 29.49 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 46.50 mill |
| Avg Daily Volume: | 0.496 mill |
| RATING 2024-04-19 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 29.49 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.62x |
| Company: PE 29.49 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$69.43 (164.48%) $43.18 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 25.23 - 27.27 ( +/- 3.87%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-06 | Pace Gary W | Sell | 1 066 | Common Stock |
| 2024-03-07 | Pace Gary W | Sell | 28 257 | Common Stock |
| 2024-03-08 | Pace Gary W | Sell | 90 000 | Common Stock |
| 2024-02-05 | Williams Kristen | Buy | 33 700 | Common Stock |
| 2024-02-05 | Gaugler Daryl | Buy | 33 700 | Common Stock |
| INSIDER POWER |
|---|
| 58.62 |
| Last 95 transactions |
| Buy: 1 581 500 | Sell: 429 616 |
Forecast:
16:00 - $26.24
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $26.24
Forecast 2: 16:00 - $26.24
Forecast 3: 16:00 - $26.24
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $26.25 (0.57% ) |
| Volume | 0.440 mill |
| Avg. Vol. | 0.496 mill |
| % of Avg. Vol | 88.84 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PCRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $27.62 | N/A | Active |
|---|
PCRX
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Latest Press Releases
2024-04-02 08:00:00 - Press Release
Pacira Biosciences To Participate In Fireside Chat At The 23rd Annual Needham Virtual Healthcare Conference
Tampa, fla., april 02, 2024 (globe newswire) -- pacira biosciences, inc. (nasdaq: pcrx) today announced that it will participate in an analyst-led fireside chat at the 23rd annual needham virtual healthcare conference at 8:00 am et on monday, april 8, 2024. live audio of the virtual event can be accessed by visiting the “events” page of the company's website at investor.pacira.com. a replay of the webcast will also be available for two weeks following the event.
2024-03-13 07:00:00 - Press Release
Pacira Biosciences Announces Pcrx-201 Granted Regenerative Medicine Advance Therapy (rmat) Designation For The Treatment Of Osteoarthritis Of The Knee
-- pcrx-201 is the first gene therapy product candidate to receive rmat designation for osteoarthritis -- -- designation supported by encouraging preliminary data from 72-patient phase 1 study --
2024-03-06 08:00:00 - Press Release
Pacira Biosciences To Participate In Fireside Chat At The Barclays 26th Annual Global Healthcare Conference
Tampa, fla., march 06, 2024 (globe newswire) -- pacira biosciences, inc. (nasdaq: pcrx) today announced that it will participate in an analyst-led fireside chat at the barclays 26th annual global healthcare conference at 1:35 pm et on wednesday, march 13, 2024 in miami. live audio of the event can be accessed by visiting the “events” page of the company's website at investor.pacira.com. a replay of the webcast will also be available for two weeks following the event.
2024-02-29 08:00:00 - Press Release
Pacira Biosciences Reports Fourth Quarter And Full-year 2023 Financial Results
— record revenues of $675 million in 2023 — — full-year gaap net income of $42 million and adjusted ebitda of $214 million — — exparel surpasses the 14 million patient mark — — conference call today at 8:30 a.m. et — tampa, fla.
2024-02-22 08:00:00 - Press Release
Pacira To Report 2023 Financial Results On Thursday February 29, 2024
Tampa, fla., feb. 22, 2024 (globe newswire) -- pacira biosciences, inc. (nasdaq:pcrx) today announced that it will report its fourth quarter and year ended december 31, 2023 financial results before the open of the u.s. markets on thursday february 29, 2024. following the release, the company will host a live conference call and webcast at 8:30 a.m. et.
Latest News
2024-03-14 09:26:11 - Zacks Investment Research
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.
2024-03-06 08:00:00 - GlobeNewsWire
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference at 1:35 PM ET on Wednesday, March 13, 2024 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
2024-03-01 07:06:04 - Zacks Investment Research
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.
2024-02-29 11:01:20 - Zacks Investment Research
Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings
The headline numbers for Pacira (PCRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
2024-02-29 10:16:21 - Zacks Investment Research
Pacira (PCRX) Matches Q4 Earnings Estimates
Pacira (PCRX) came out with quarterly earnings of $0.89 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.80 per share a year ago.
2024-01-03 08:00:00 - GlobeNewsWire
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference at 8:15 AM PT (11:15 AM EST) on Wednesday, January 10, 2024. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
2023-11-02 14:17:21 - Zacks Investment Research
Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated
Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales.
2023-10-26 08:00:00 - GlobeNewsWire
Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023
TAMPA, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday November 2, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.
2023-09-06 08:00:00 - GlobeNewsWire
Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
TAMPA, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced its participation in an analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference. The pre-recorded audio of the virtual event can be accessed beginning Monday, September 11th at 7:00AM ET by visiting the “Events” page of the company's website at investor.pacira.com . A replay of the webcast will also be available for two weeks.
2023-08-02 14:12:24 - Zacks Investment Research
Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated
Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.